Effects of Itraconazole in Tinea Corporis in All Age Group

Abstract

Introduction: Tinea corporis, commonly known as ringworm, is a superficial fungal infection predominantly affecting the glabrous (smooth and bare) skin apart from the scalp, feet, and groin. Current research continues to explore the scope of itraconazole's utility in tinea corporis, with studies focusing on optimizing dosing regimens and minimizing side effects in different age groups.

Methods and materials: This study employed a cross-sectional prospective design to assess the effectiveness and safety of itraconazole in treating Tinea corporis across different age groups, in the Department of Dermatology, Mymensingh Medical College and Hospital, Mymensingh, Bangladesh, from July 2023 to January 2024.  A total of 472 patients were selected for his study. Data were analyzed using SPSS and significance was set at p<0.05.

Results: Initial findings at the two-week follow-up indicated that 58-67% of participants across age groups experienced complete clearing of lesions, with additional significant improvements noted. By the four-week follow-up, the rates of complete clearing had increased: 82% in children (2-12 years), 86% in adolescents and young adults (13-35 years), 89% in middle-aged adults (36-60 years), and 88% in the elderly (>60 years). Despite these high rates of efficacy, statistical analysis determined that there were no significant differences between age groups (p > 0.05).

Conclusion: The study demonstrates that itraconazole effectively treats Tinea Corporis across various age groups with consistent efficacy. The results show significant lesion clearance and symptom resolution within four weeks, with no notable differences in response across age demographics.